stockaxis

Krsnaa Diagnostics Ltd

Quarterly Result - Q3FY25

Krsnaa Diagnostics Ltd

Hospital & Healthcare Services

Current

CMP
Rs. 712.40
Rating:
Hold
February 12, 2025

Previous

Rating:
Hold

Stock Info

BSE
543328
NSE
KRSNAA
Bloomberg
KRSNAA:IN
Reuters
KRSN.NS
Sector
Hospital & Healthcare Services
Face Value (Rs)
5
Equity Capital (Rs cr)
16
Mkt Cap (Rs cr)
2350.69
52w H/L (Rs)
1044.00 - 528.05
Avg Daily Vol (BSE+NSE)
2,217

Shareholding Pattern

(as on 31-Dec)
%
Promoter
27.24
FIIs
4.04
DIIs
14.46
Public & Others
54.27
Source: Ace equity, stockaxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
-0.12
-9.74
19.96
Sensex
-0.21
-3.18
7.17
Source: Ace equity, stockaxis Research

Indexed Stock Performance

Krsnaa Diagnostics Ltd Sensex
Krsnaa Diagnostics Ltd
Source: Ace equity, stockaxis Research

Financial Highlights:

Particulars (in Rs. Cr) Q3FY25 Q3FY24 YoY (%) Q2FY25 QoQ (%)
Revenue from Operations 175.00 158.00 10.00% 186.00 -6.00%
EBITDA 45.00 37.00 21.00% 49.00 -9.00%
EBITDA Margin (%) 25.81% 23.62% 221 bps 26.51% (68) bps
PAT 19.00 13.00 50.00% 20.00 -1.00%
EPS (Rs.) 6.00 4.00 48.00% 4.00 48.00%

Source: Company Filings; stockaxis Research

Q3FY25 Result Highlights
Krsnaa Diagnostics delivered an in-line set of numbers for the quarter ended Q3FY25. Consolidated net sales rose 10% to Rs.174.5 cr as compared to Rs.158 cr registered in the same quarter of the preceding fiscal. Consolidated EBITDA saw a robust growth of 21% YoY to Rs.45 cr while the EBITDA margin improved 221 bps YoY to 27%. This improvement was driven by: (1) operating leverage from new centers; and (2) business restructuring - business consultant services in-house (vs. outsourced earlier). PAT jumped 50% YoY to Rs.19.4 cr aided by healthy topline growth and robust operational performance.

Operational Highlights

  • Krsnaa now operates 49 NABL–accredited pathology laboratories in Government hospitals across seven states: Maharashtra, Punjab, Himachal Pradesh, Odisha, Assam, Manipur, and Rajasthan.
  • Successfully launched retail operations across four States, Under the brand name “RPL”.
  • KRSNAA has been honored with the “Leading HR Transformation Award” at the esteemed India HR Summit & Awards 2024.
  • Krsnaa expanded its presence by establishing 284 additional collection centers across the nation.

Key Conference Call Takeaways

Guidance: (i) The management remains firm on its 25% revenue growth guidance with a sustainable EBITDAM of ~25%. (ii) Current ROCE is 10-12%, with improvement expected through an asset-light model, B2C expansion, and efficiency.

Key Developments During the Quarter 

  • Jharkhand: KRSNAA secured a tender for 2 new centers expected to beoperational by Q1FY26.
  • Rajasthan tender: KRSNAA has fulfilled all its obligations required for the tenderand is awaiting the judiciary to take its due course. Management has said thatdiscussions are currently ongoing with the new government. The company is ontrack to maintain its growth trajectory even without the tender.
  • BMC Project – KRSNAA has reported that operational issues with BMC have beenresolved, and the project has been completed. The tender for renewal isexpected to be introduced with a larger scope. The company is confident insecuring the tender due to its experience and execution capabilities.
  • Operational challenges remained in Assam and Karnataka, which has affectedvolumes this quarter.

Receivable Days

  • Receivable days currently average around 60-65 days, however, HP andKarnataka reported receivable days at ~120 days.
  • Measures are in place to reduce receivable days in these states to 90 days by year end. KRSNAA also plans to normalize company-wide receivable days to 65-70 days by 2026.

Entry into Retail Diagnostics

  • Key development during Q3 has been the company’s foray into retail diagnostics with the launch of the “RPL” brand in 4 states - Maharashtra, Punjab, Assam, and Odisha. The venture will leverage and capitalize on the existing PPP infra.
  • Currently KRSNAA has a presence of 80 touchpoints with an aim to expand the retailnetwork to 500 touchpoints by FY26.
  • KRSNAA aspires for a higher B2C revenue contribution to total revenue.
  • The growth in retail ventures may be gradual but is expected to increase insubsequent years.

Testing Infrastructure

  • KRSNAA has 178 CT/MRI centers across the country as of Q3FY25.
  • United Imaging – KRSNAA has ordered 7 machines of which 2 have beenreceived. 5 machines are expected to be received by February/March’25.
  • Maharashtra: 40 CT scan machines have been commissioned. 15 CT scanmachines and 17 MRI machines are expected to be operationalized soon withrevenue realization from 1QFY26.
  • KRSNAA reported Delays in Maharashtra and Madhya Pradesh MRI installationsdue to site handovers.

Apulki Healthcare Partnership

  • The first Apulki hospital (in Baner) is expected to be operational by April (delayedfrom earlier guidance of January/February’25).

Return on Capital

  • KRSNAA reported ROCE at 12% which is subdued due to past investments and delayed realizations.
  •  An asset light model in the retail venture and other efficiency initiatives are expected to help improve ROCE going forward.

Ongoing Capex

  • Radiology – 90 projects currently under implementation.
  • Pathology – 489 collection centers to be added
Krsnaa Diagnostics

Outlook & valuation

Krsnaa Diagnostics delivered steady earnings in Q3FY25. The company has received the signed agreement from the Medical Superintendent, Sadar Hospital, Ranchi, Jharkhand for the commission, install, operate, and maintain the Radiology services (CT and MRI) on a public-private partnership basis at Sadar Hospital, Purulia Road, Ranchi. Also, the company has received the signed agreement from the Ranchi Institute of Neuropsychiatry & Allied Services (RINPAS), for the supply, installation, commission, operation, and maintain the Radiology Centre (CT&MRI) and pathology laboratory services on a PPP basis. Apart from the above-mentioned tenders, Krsnaa has a pipeline to execute 52 radiology centres and 1600 pathology centers. All these tenders are between 5-12 years in duration, thus providing long-term revenue visibility for the company. Management is confident of achieving topline growth of 25-30% in FY25 and an EBITDA Margin of 25-26%.

The company has strengthened its position in the oncology and cardiac diagnostics space by securing an exclusive 30+ year partnership with Apulki’s cancer and cardiac hospitals. We expect this partnership to be a big revenue driver in the medium to long term. Krsnaa is also looking to scale up its presence in the B2C segment, which will have differential pricing but will still be competitive compared to market rates. This will help improve margins and lead to a better working capital cycle.  KRSNAA has also started to strengthen its B2B initiative, wherein itservices hospitals, nursing homes, and laboratories. They are presently serving more than 400 B2B labs, hospitals, and nursing homes and intend to expand to 1,000 in FY26. These initiatives will leverage the infrastructure laid out for B2G contracts and hence we expect to see meaningful leverage emerging from the business going forward.

Given the leading position of KDL as a diagnostics service provider, a strong revenue growth outlook is to be driven by ongoing capex and scope for profit margin expansion. At a CMP of Rs.709, the stock is trading at 19.4x FY26E. We recommend a HOLD rating on the stock.

Consolidated Financial statements

Profit & Loss statement

Particulars (in Rs. Cr) Q3FY25 Q3FY24 YoY (%) Q2FY25 QoQ (%)
Revenue from Operations 175.00 158.00 10.00% 186.00 -6.00%
Cost of Goods Sold 40.00 34.00 16.00% 45.00 -11.00%
Gross Profit 135.00 124.00 9.00% 141.00 -5.00%
Gross Profit Margin (%) 77.14% 78.30% (116) bps 75.90% 124 bps
Employee Benefit Expenses 36.00 30.00 21.00% 35.00 2.00%
Fees to Hospitals and Others 14.00 18.00 -26.00% 17.00 -22.00%
Other Expenses 40.00 39.00 4.00% 40.00 1.00%
EBITDA 45.00 37.00 21.00% 49.00 -9.00%
EBITDA Margin (%) 25.81% 23.62% 221 bps 26.51% (68) bps
Depreciation 23.00 21.00 7.00% 22.00 2.00%
EBIT 22.00 16.00 38.00% 27.00 -18.00%
Finance Cost 6.00 4.00 48.00% 6.00 -4.00%
Other Income 9.00 4.00 127.00% 5.00 101.00%
Profit Before Tax 26.00 16.00 58.00% 25.00 0.00%
Taxes 6.00 3.00 94.00% 6.00 4.00%
PAT 19.00 13.00 50.00% 20.00 -1.00%
EPS (Rs.) 6.00 4.00 48.00% 4.00 48.00%